Postgraduate medicine
-
Postgraduate medicine · May 2014
Multicenter Study Clinical TrialFesoterodine prescription fill patterns and evaluation of the YourWay patient support plan for patients with overactive bladder symptoms and physicians.
Adherence with oral medication for overactive bladder syndrome is suboptimal. To improve adherence, the YourWay plan was developed to assist patients and health care providers in defining treatment expectations and facilitating communication. ⋯ Most patients adopted YourWay components and viewed the plan positively, although adherence remained a challenge.
-
Postgraduate medicine · Sep 2013
Randomized Controlled Trial Multicenter StudyLower-dose diclofenac submicron particle capsules provide early and sustained acute patient pain relief in a phase 3 study.
Non-steroidal anti-inflammatory drugs are prescribed for the treatment of patients with acute pain but use of such analgesics is associated with dose-dependent adverse events (AEs). Diclofenac submicron particle capsules have been developed using SoluMatrix technology to provide analgesia at lower doses than available solid oral dosing forms. Our study evaluated the analgesic efficacy and safety of lower-dose diclofenac submicron particle capsules in patients with acute pain following elective surgery. ⋯ Lower-dose diclofenac submicron particle capsules provided effective analgesia in this phase 3 clinical study in patients with acute pain and are a potentially promising option for the treatment of patients with acute pain.
-
Postgraduate medicine · Jul 2012
Multicenter Study Clinical TrialSafety and efficacy of the LAP-BAND AP® adjustable gastric band in the treatment of obesity: results at 2 years.
The objective of this analysis is to report interim, 2-year results for morbidly obese patients who have undergone laparoscopic adjustable gastric banding in the LAP-BAND AP® EXperience (APEX) trial. ⋯ The LBAP safely and effectively facilitated weight loss in morbidly obese patients, with clinically meaningful improvements in quality of life and obesity-related comorbidities. The durability of these results will be further described with additional follow-up through 5 years.
-
Postgraduate medicine · Sep 2011
Multicenter Study Clinical TrialOpioid titration and conversion in patients receiving morphine sulfate and naltrexone hydrochloride extended release capsules.
To determine the number of steps and identify characteristics associated with attaining a stable dose of morphine sulfate and sequestered naltrexone extended release capsules (MS-sNT). ⋯ The study provides information about anticipated rates of achieving stable opioid dose in patients who received MS-sNT for up to 1 year to manage chronic, moderate-to-severe pain. Both opioid-naïve and opioid-experienced patients achieved a stable dose of MS-sNT, generally in ≤ 2 steps. Opioid experience and previous opioid use may influence ability to achieve a stable dose and number of steps required. More studies are needed on the anticipated experience of opioid titration/conversion to help physicians and patients set expectations for initiation of and conversion between opioid therapies.
-
Postgraduate medicine · Jul 2010
Randomized Controlled Trial Multicenter StudyMorphine sulfate and naltrexone hydrochloride extended release capsules in patients with chronic osteoarthritis pain.
To assess the efficacy and safety of morphine sulfate and naltrexone hydrochloride extended release capsules (EMBEDA; MS-sNT), which contain morphine sulfate pellets with a sequestered naltrexone core, in treating patients with chronic, moderate-to-severe osteoarthritis (hip or knee) pain. ⋯ MS-sNT provided effective analgesia in patients with chronic, moderate-to-severe osteoarthritis pain, with a safety profile typical of morphine-containing products. Naltrexone sequestered in MS-sNT had no clinically relevant effect when MS-sNT was taken as directed.